Institute for Cancer Genetics and Informatics
The Institute for Cancer Genetics and Informatics performs research in biomedicine and informatics to develop and establish new methods for diagnosis and prognostication and applies these methods to large clinical series in collaboration with the clinical departments and Department of Pathology at Oslo University Hospital. Successful trials are then made applicable and offered as routine clinical practice, preferably established and performed by us.
In recent years, we have focused on new technologies, often referred to as artificial intelligence (AI). We continue establishing new knowledge in the laboratory and then taking it to the clinic. This strategy requires an interdisciplinary approach, and close integration between scientists, technologists and clinicians. Our basic research strategy is to focus on nucleomics, our innovation strategy is focused on microscopy based image analysis, and our overall goal is to enable better cancer treatment through new methods for improved diagnosis and prognosis of cancer.
The Institute for Cancer Genetics and Informatics is located at Oslo Cancer Cluster Innovation Park, next to Radiumhospitalet at Oslo University Hospital. The Institute leads the Norwegian Research Council Lighthouse Project DoMore!, and was part of Centre for Cancer Biomedicine, appointed Centre for excellence in research by the Norwegian Research Council until the project ended in 2017. The Institute’s work consistently supports the high international standing of the Oslo University Hospital, both through our contribution to medical services and through our research contribution.
The institute is headed by Håvard E. Danielsen and has around 70 employees.